BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 2957448)

  • 1. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T; Shu S
    J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
    Shu S; Chou T; Rosenberg SA
    Cancer Res; 1987 Mar; 47(5):1354-60. PubMed ID: 3102046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell immunity to murine Moloney sarcoma virus-induced tumours: L3T4+ T cells are necessary for resistance to primary sarcoma growth, but Lyt-2+ T cells are required for resistance to secondary tumour cell challenge.
    Bateman WJ; Jenkinson EJ; Owen JJ
    Immunology; 1987 Jul; 61(3):317-20. PubMed ID: 2956180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K; Chang AE; Shu SY
    Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Requirements for the generation of a Lyt-2+ T-cell proliferative response to a syngeneic tumor in the absence of L3T4+ T-cells.
    Kern DE; Klarnet JP; Cheever MA; Greenberg PD
    Cancer Res; 1990 Oct; 50(19):6256-63. PubMed ID: 2144789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY; Chou T; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S; Rosenberg SA
    J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrasuppressor cells that break oral tolerance are antigen-specific T cells distinct from T helper (L3T4+), T suppressor (Lyt-2+), and B cells.
    Kitamura K; Kiyono H; Fujihashi K; Eldridge JH; Green DR; McGhee JR
    J Immunol; 1987 Nov; 139(10):3251-9. PubMed ID: 3500210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lyt-2+ cells. Requirements for concanavalin A-induced proliferation and interleukin 2 production.
    Kern DE; Lachmann LB; Greenberg PD
    J Immunol; 1987 Nov; 139(9):2880-7. PubMed ID: 2959723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. I. Requirement of Lyt-1 dull L3T4 bright normal T cells for the induction of thyroiditis.
    Sugihara S; Izumi Y; Yoshioka T; Yagi H; Tsujimura T; Tarutani O; Kohno Y; Murakami S; Hamaoka T; Fujiwara H
    J Immunol; 1988 Jul; 141(1):105-13. PubMed ID: 2967864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of L3T4+ and Lyt-2+ T cells in the IgE response and immunity to Nippostrongylus brasiliensis.
    Katona IM; Urban JF; Finkelman FD
    J Immunol; 1988 May; 140(9):3206-11. PubMed ID: 2966208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.
    Via CS; Sharrow SO; Shearer GM
    J Immunol; 1987 Sep; 139(6):1840-9. PubMed ID: 2957440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation.
    Ohnishi K; Bonavida B
    J Immunol; 1987 Jun; 138(12):4524-9. PubMed ID: 2953807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of L3T4-positive T lymphocytes in the generation of anti-tumor immunity in the mouse.
    Yamamoto H; Takata M; Fujimoto S
    Jpn J Cancer Res; 1987 Feb; 78(2):176-84. PubMed ID: 2951356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular subsets involved in cell-mediated immunity to murine Plasmodium yoelii 17X malaria.
    Mogil RJ; Patton CL; Green DR
    J Immunol; 1987 Mar; 138(6):1933-9. PubMed ID: 3102605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.